Berlin, Germany (PRWEB) December 1, 2008
At the annual Xybion User Group Meeting, Xybion announced the launch of a full suite of Developmental and Reproductive toxicology functions as part of its flagship PATH/TOX SYSTEM data management system for safety assessment.
By extending the in-vivo and post-mortem areas of PATH/TOX SYSTEM to account for maternal, embryo-fetal and pup data assessment capabilities, Xybion allows its current client community to leverage the training, validation and infrastructure already in place for standard toxicology studies for rapid deployment of these new functions. New clients benefit from the ability to implement a single product that automatically supports all of their safety assessment requirements.
Specifically, PATH/TOX SYSTEM now supports common study types such as:
- Multi-generation - up to F3
- Embryo-fetal Development
- Pre- and Post-natal Development
- Developmental Toxicity
- Developmental Neurotoxicity
- Juvenile Toxicology
Dr. Pradip Banerjee, CEO of Xybion, stated that "with this launch of the Repro module Xybion now offers a single data management system to acquire, manage and report data for every type of safety assessment study currently conducted at any facility in the world. Xybion's PATH/TOX SYSTEM is the only solution designed from the ground up to become 'One System' already fully integrated to support such a wide variety of GLP and non-GLP study designs that it needs no further third-party tools and integration costs unlike most other systems."
Xybion's PATH/TOX SYSTEM is the most comprehensive pathology and toxicology data management system available today. It integrates numerous laboratory activities, including in-life toxicology, pharmacy, clinical pathology, reproductive toxicology and teratology, necropsy and histopathology. The System is protocol-driven, and is designed to promote compliance with regulatory data management requirements including full compliance with 21CFR part 11.
Xybion Corp., a lifesciences eR&D systems and management services firm, is engaged in the development, maintenance and support of a software system that addresses all aspects of preclinical data acquisition, management, reporting, validation and implementation services. Xybion's products are used by some of the largest and most prestigious pharmaceutical and chemical companies in the world to assess compound safety and to reduce the time involved in bringing a drug or chemical to market. Xybion Corp is headquartered in Cedar Knolls, NJ.